Medical Device | April 23, 2026
Medtronic launches adaptive deep brain stimulation system for Parkinson’s in India
The system is powered by BrainSense technology, which has received approval from USFDA
The system is powered by BrainSense technology, which has received approval from USFDA
The hospital said the new centre will improve access to specialised interventions such as Deep Brain Stimulation
Milestone marks a major leap toward real-time, personalised neuromodulation therapy as India’s Parkinson’s burden rises sharply
The conditional, time-limited approval comes through a joint effort with RACTHERA, a joint venture in which Sumitomo Chemical holds a 66.6% stake and Sumitomo Pharma holds 33.4%
Built on the Percept Platform and enhanced with BrainSense technology, the system can adjust stimulation levels in real time, responding to brain signals without manual intervention
The move follows encouraging Phase I data and a series of regulatory wins from the U.S. Food and Drug Administration
TED?A9 is part of S.Biomedics’ expanding pipeline of stem-cell-based therapies, developed using the company’s proprietary targeted embryonic stem cell differentiation platform
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Stalevo Tablets
The upcoming Phase I trial will test the safety, tolerability, and pharmacokinetics of ISM8969 in healthy volunteers and determine the optimal dosing for future studies
The RMAT designation accelerates the development of regenerative medicine therapies for serious or life-threatening diseases
Subscribe To Our Newsletter & Stay Updated
